Cartesian Therapeutics (RNAC) Equity Ratio (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Equity Ratio data on file, last reported at 0.51 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.51, down 864.38% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.51 (down 864.38% YoY), and the FY2025 annual result was 0.43, down 2623.82% from the prior year.
• Equity Ratio slipped to 0.51 in Q1 2026 per RNAC's latest filing, from 0.43 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.57 in Q3 2023 and troughed at 1.44 in Q4 2023.
• A 5-year average of 0.01 and a median of 0.01 in 2025 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2022 and 2025: Equity Ratio soared 2137.2% in 2022, then sank 5923.46% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.57 in 2022, then slumped by 355.12% to 1.44 in 2023, then jumped by 98.92% to 0.02 in 2024, then slumped by 2623.82% to 0.43 in 2025, then declined by 20.59% to 0.51 in 2026.
• Business Quant data shows RNAC's Equity Ratio at 0.51 in Q1 2026, 0.43 in Q4 2025, and 0.1 in Q3 2025.